Learn More
The confinement of multiple myeloma (MM) to the bone marrow microenvironment requires an invasive bone marrow biopsy to monitor the malignant compartment. The existing clinical tools used to determine treatment response and tumor relapse are limited in sensitivity mainly because they indirectly measure tumor burden inside the bone marrow and fail to capture(More)
It is now clear that multiple myeloma (MM), a neoplasm of the most differentiated cells of the B lineage, is associated with a complex range of numerical, phenotypic and functional abnormalities within the dendritic cell (DC) and T-cell compartments. Malignant plasma cells use a broad range of subversive tactics to avoid recognition by the immune system,(More)
  • 1